Abstract: Aspects of the disclosure relates to providing deliveries of goods using autonomous vehicles. For instance, a first request for goods identifying a delivery location may be used to send a second request for an autonomous vehicle to deliver the goods to the delivery location. A first notification indicating that the autonomous vehicle has been loaded with the one or more goods at a loading location may be received. A second notification indicating arrival of the autonomous vehicle at the delivery location may be received. In response to receiving the second notification, a third notification may be sent indicating that the one or more goods has arrived at the delivery location. In response, a third request to open a door of the autonomous vehicle may be received. In response, a signal may be sent in order to unlock or open the door and provide access to the one or more goods.

Abstract: Compositions and methods for efficient delivery of therapeutic agents in vivo are provided. Typically, the compositions are in the form of polymeric particles formed from one or more therapeutic agent complexed with a polycationic polymer which is further encapsulated in one or more amphiphilic polymers, preferably diblock copolymer of a polyalkylene oxide and a polyester such as poly(D,L-lactide)-poly(ethylene glycol) (PLA-PEG). In the preferred embodiments, the chemotherapeutic agent reduces, or inhibits N-glycosylation of one or more receptor tyrosine kinases of cancer cells. Methods of using the particles to treat cancer are also provided.

Abstract: Compositions and methods for efficient delivery of therapeutic agents in vivo are provided. Typically, the compositions are in the form of polymeric particles formed from one or more therapeutic agent complexed with a polycationic polymer which is further encapsulated in one or more amphiphilic polymers, preferably diblock copolymer of a polyalkylene oxide and a polyester such as poly(D,L-lactide)-poly(ethylene glycol) (PLA-PEG). In the preferred embodiments, the chemotherapeutic agent reduces, or inhibits N-glycosylation of one or more receptor tyrosine kinases of cancer cells. Methods of using the particles to treat cancer are also provided.